TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

,

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Elisabeth Quoix, et al.
The Lancet Oncology, December 2015, 17: 212–23 – Download the article
Publication

Par alcyon|2019-07-02T15:19:26+02:00décembre 18th, 2015|Publication, TG4010|Commentaires fermés

À propos de l'auteur : alcyon